



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/676,053	09/28/2000	James Oliver Dolly	17044DIV1 (AP)

Carlos A Fisher
Allergan Inc
T2-7H
2525 Dupont Drive
Irvine, CA 92612

RESPONSE DUE

FORMALITIES LETTER



OC000000005568831

Date Mailed: 11/20/2000

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase PatentIn Software, call (703) 306-2600

*A copy of this notice **MUST** be returned with the reply.*

Dorothy Bell
Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Box sequence

0300

DEC 1 2000

EL385493182US

DOCKET NO: 17044DIV

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dolly et al.)
Serial No.: 09/676,053)
Filed: September 28, 2000)
For: MODIFICATION OF)
CLOSTRIDIAL TOXINS FOR USE)
AS TRANSPORT PROTEINS)
Examiner: Unknown)

Group Art Unit: Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail bearing Label No: EL385493182US and addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on:

Date of Deposit: 12/19/00

Person making Deposit: Bonnie Ferguson

Signature: Bonnie Ferguson

Date of Signature: 12/19/00

CERTIFICATE OF EXPRESS MAILING

Customer Service Center
Initial Patent Examination Division
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed are a patent application for filing pursuant to 37 CFR 1.53(b). Specifically, accompanying this communication please find:

1. Reply to Notice to Comply with Sequence Rules and Supplemental Preliminary Amendment (3 Pages)
2. Formalities Letter
3. Disk
4. Substitute Sequence Listing

Respectfully submitted,

Bonnie S. Ferguson

Date: 12/19/00

ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920
Fax: 714-246-4249